Patent ID: 11884720
Assignee: AMGEN INC.
Field: Biotechnology (Chemistry)
Classification: CPC C  A | IPC C

Claim 4:
5. The bispecific antibody construct according to claim 1 comprising in an N- to C-terminal order:
(a) the first binding domain comprising the amino acid sequence selected from the group consisting of: SEQ ID NO: 169, SEQ ID NO: 179, SEQ ID NO: 189, SEQ ID NO: 199, and SEQ ID NO: 209;
a peptide linker comprising the amino acid sequence selected from the group consisting of: SEQ ID NOs: 1-9; and
the second binding domain comprising the amino acid sequence selected from the group consisting of: SEQ ID NO: 19, SEQ ID NO: 28, SEQ ID NO: 37, SEQ ID NO: 46, SEQ ID NO: 55, SEQ ID NO: 64, SEQ ID NO: 73, SEQ ID NO: 82, SEQ ID NO: 91, SEQ ID NO: 100, and SEQ ID NO: 103; and
optionally, a His-tag comprising the amino acid sequence of SEQ ID NO: 10;

(b) the first binding domain comprising the amino acid sequence selected from the group consisting of: SEQ ID NO: 169, SEQ ID NO: 179, SEQ ID NO: 189, SEQ ID NO: 199, and SEQ ID NO: 209;
a peptide linker comprising the amino acid sequence selected from the group consisting of: SEQ ID NOs: 1-9;
the second binding domain comprising the amino acid sequence selected from the group consisting of: SEQ ID NO: 19, SEQ ID NO: 28, SEQ ID NO: 37, SEQ ID NO: 46, SEQ ID NO: 55, SEQ ID NO: 64, SEQ ID NO: 73, SEQ ID NO: 82, SEQ ID NO: 91, SEQ ID NO: 100, and SEQ ID NO: 103;
optionally, a peptide linker comprising the amino acid sequence selected from the group consisting: of SEQ ID NOs: 1-9; and
an albumin polypeptide comprising the amino acid sequence selected from the group consisting of: SEQ ID NOs: 104-133; and
optionally, a His-tag comprising the amino acid sequence of SEQ ID NO: 10;

(c) a neonatal Fc receptor (FcRn) binding peptide comprising the amino acid sequence of QRFVTGHFGGLX1PANG (SEQ ID NO: 135) whereas X1 is Y or H;
the first binding domain comprising the amino acid sequence selected from the group consisting of: SEQ ID NO: 169, SEQ ID NO: 179, SEQ ID NO: 189, SEQ ID NO: 199, and SEQ ID NO: 209;
a peptide linker comprising the amino acid sequence selected from the group consisting of: SEQ ID NOs: 1-9;
the second binding domain comprising the amino acid sequence selected from the group consisting of: SEQ ID NO: 19, SEQ ID NO: 28, SEQ ID NO: 37, SEQ ID NO: 46, SEQ ID NO: 55, SEQ ID NO: 64, SEQ ID NO: 73, SEQ ID NO: 82, SEQ ID NO: 91, SEQ ID NO: 100, and SEQ ID NO: 103; and
a neonatal Fc receptor (FcRn) binding peptide comprising the amino acid sequence of QRFVTGHFGGLHPANG (SEQ ID NO: 137) or QRFCTGHFGGLHPCNG (SEQ ID NO: 139); and
optionally, a His-tag comprising the amino acid sequence of SEQ ID NO: 10;

(d) the first binding domain comprising the amino acid sequence selected from the group consisting of: SEQ ID NO: 169, SEQ ID NO: 179, SEQ ID NO: 189, SEQ ID NO: 199, and SEQ ID NO: 209;
a peptide linker comprising the amino acid sequence selected from the group consisting of: SEQ ID NOs: 1-9;
the second binding domain comprising the amino acid sequence selected from the group consisting of: SEQ ID NO: 19, SEQ ID NO: 28, SEQ ID NO: 37, SEQ ID NO: 46, SEQ ID NO: 55, SEQ ID NO: 64, SEQ ID NO: 73, SEQ ID NO: 82, SEQ ID NO: 91, SEQ ID NO: 100, and SEQ ID NO: 103; and
a Fc polypeptide comprising the amino acid sequence of SEQ ID NO: 144; and a Fc polypeptide comprising the amino acid sequence of SEQ ID NO: 145;

(e) the first binding domain comprising the amino acid sequence selected from the group consisting of: SEQ ID NO: 169, SEQ ID NO: 179, SEQ ID NO: 189, SEQ ID NO: 199, and SEQ ID NO: 209;
a Fc polypeptide comprising the amino acid sequence of SEQ ID NO: 146;
the second binding domain polypeptide comprising the amino acid sequence selected from the group consisting of: SEQ ID NO: 19, SEQ ID NO: 28, SEQ ID NO: 37, SEQ ID NO: 46, SEQ ID NO: 55, SEQ ID NO: 64, SEQ ID NO: 73, SEQ ID NO: 82, SEQ ID NO: 91, SEQ ID NO: 100, and SEQ ID NO: 103; and
a Fc polypeptide comprising the amino acid sequence of SEQ ID NO: 147;

(f) the first binding domain comprising the amino acid sequence selected from the group consisting of: SEQ ID NO: 169, SEQ ID NO: 179, SEQ ID NO: 189, SEQ ID NO: 199, and SEQ ID NO: 209;
a Fc polypeptide comprising the amino acid sequence of SEQ ID NO: 148;
the second binding domain polypeptide comprising the amino acid sequence selected from the group consisting of: SEQ ID NO: 19, SEQ ID NO: 28, SEQ ID NO: 37, SEQ ID NO: 46, SEQ ID NO: 55, SEQ ID NO: 64, SEQ ID NO: 73, SEQ ID NO: 82, SEQ ID NO: 91, SEQ ID NO: 100, and SEQ ID NO: 103; and
a Fc polypeptide comprising the amino acid sequence of SEQ ID NO: 149; or

(g) the first binding domain comprising the amino acid sequence selected from the group consisting of: SEQ ID NO: 169, SEQ ID NO: 179, SEQ ID NO: 189, SEQ ID NO: 199, and SEQ ID NO: 209;
a peptide linker comprising the amino acid sequence selected from the group consisting of: SEQ ID NOs: 1-9;
the second binding domain comprising the amino acid sequence selected from the group consisting of: SEQ ID NO: 19, SEQ ID NO: 28, SEQ ID NO: 37, SEQ ID NO: 46, SEQ ID NO: 55, SEQ ID NO: 64, SEQ ID NO: 73, SEQ ID NO: 82, SEQ ID NO: 91, SEQ ID NO: 100, and SEQ ID NO: 103; and
a Fc polypeptide comprising the amino acid sequence of SEQ ID NO: 150.